To achieve the selective release of therapeutic agents at the tumor regions, Shapiro et al. further manufactured strains that produced tumor-suppressing anti-PD-L1 and anti-CTLA4 antibodies only when heated to a trigger temperature of 42-43°C by introducing a temperature-actuated genetic state switch. Here, CTLA4 is linked to neoplasm.